SCHEMBL29356013

SCHEMBL29356013

Oc1cccc(-c2ccccc2)c1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 10/20 0.84
HSD17B2 P37059 10/20 0.84
CYP3A4 P08684 3/20 0.84
CYP2C9 P11712 2/20 0.84
ESR1 P03372 5/20 0.60
ESR2 Q92731 4/20 0.60
CYP1A2 P05177 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2B6 P20813 1/20 0.60
CYP2C19 P33261 1/20 0.60
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
ALDH1A1 P00352 2/20 0.58
LMNA P02545 2/20 0.58
HSD17B10 Q99714 2/20 0.58
CA12 O43570 1/20 0.58
CA2 P00918 1/20 0.58
CA5A P35218 1/20 0.58
CA9 Q16790 1/20 0.58
CA14 Q9ULX7 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL51869 1.00 HSD17B1 (0.84) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL19845791 0.97 HSD17B1 (0.80) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL2682114 0.97 HSD17B1 (0.90) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
Hydrochloric Acid SCHEMBL5069276 0.97 HSD17B1 (0.80) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
Hydrochloric Acid SCHEMBL30534237 0.97 HSD17B1 (0.80) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL28704509 0.97 HSD17B1 (0.80) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL29832647 0.97 HSD17B1 (0.90) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL11819204 0.97 HSD17B1 (0.80) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL14973515 0.97 HSD17B1 (0.80) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL28363523 0.97 HSD17B1 (0.79) HSD17B1HSD17B2CYP3A4CYP2C9ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4440315-A1 FUNGICIDAL COMPOSITIONS Syngenta Crop Protection AG (CH) 2024-10-09 EP claimed
EP-4392414-A1 INHIBITORS OF NLRP3 PTC Therapeutics, Inc. (US) 2024-07-03 EP claimed
WO-2023099460-A1 FUNGICIDAL COMPOSITIONS SYNGENTA CROP PROTECTION AG (CH) 2023-06-08 WO claimed
WO-2023028534-A1 INHIBITORS OF NLRP3 PTC THERAPEUTICS, INC. (US) 2023-03-02 WO claimed
US-20260137809-A1 GENE THERAPY VECTORS FOR TREATMENT OF CANCER SIREN BIOTECHNOLOGY INC (US) 2026-05-21 US disclosed
EP-4727359-A1 FUNGICIDAL COMPOSITIONS Syngenta Crop Protection AG (CH) 2026-04-22 EP disclosed
EP-3903360-B1 ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME LG DISPLAY CO LTD (KR) 2026-04-01 EP disclosed
EP-4658074-A1 FUNGICIDAL COMPOSITIONS Syngenta Crop Protection AG (CH) 2025-12-10 EP disclosed
EP-4627095-A2 GENE THERAPY VECTORS FOR TREATMENT OF CANCER Siren Biotechnology, Inc. (US) 2025-10-08 EP disclosed
EP-4626986-A1 INKJET INKS CONTAINING AMINE MODIFIED SILICONE Kao Corporation (JP) 2025-10-08 EP disclosed
WO-2025202499-A1 FUNGICIDAL COMPOSITIONS SYNGENTA CROP PROTECTION AG (CH) 2025-10-02 WO disclosed
WO-2025202482-A1 FUNGICIDAL COMPOSITIONS SYNGENTA CROP PROTECTION AG (CH) 2025-10-02 WO disclosed
US-20230015875-A1 Ion Channel Antagonists/Blockers and Uses Thereof SHANGHAI EAST HOSPITAL (CN) 2023-01-19 US disclosed
EP-4114184-A1 FUNGICIDAL COMPOSITIONS Syngenta Crop Protection AG (CH) 2023-01-11 EP disclosed
EP-4114183-A1 FUNGICIDAL COMPOSITIONS Syngenta Crop Protection AG (CH) 2023-01-11 EP disclosed
US-11474100-B2 Chromophore-labeled oligosaccharide markers and methods of use thereof HONG KONG BAPTIST UNIVERSITY (HK) 2022-10-18 US disclosed
EP-4017244-A1 APPARATUS AND METHOD FOR REDUCING DUST DEVELOPMENT IN PRECISION DRILL SOWING SYNGENTA PARTICIPATIONS AG (CH) 2022-06-29 EP disclosed
EP-4017242-A1 APPARATUS AND METHOD FOR CONVERTING EXISTING SOWING EQUIPMENT SYNGENTA PARTICIPATIONS AG (CH) 2022-06-29 EP disclosed
CN-114401935-A Ion channel antagonists/blockers and uses thereof 上海市东方医院(同济大学附属东方医院) 2022-04-26 CN disclosed
EP-3941466-A1 METHODS OF TREATING BORDERLINE PERSONALITY DISORDER Oryzon Genomics, S.A. (ES) 2022-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230015875-A1 Ion Channel Antagonists/Blockers and Uses Thereof CACNA1F, CACNA1S, CACNA1D HSD17B1 1222/4885HSD17B2 1261/4885CYP3A4 538/4885
US-20260137809-A1 GENE THERAPY VECTORS FOR TREATMENT OF CANCER STAT1, IRF3, STAT3 HSD17B1 4698/4885HSD17B2 4772/4885CYP3A4 4489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.